QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Viking Therapeutics (VKTX) Stock Forecast & Price Target

$28.89
+4.41 (+18.01%)
(As of 02/8/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Viking Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$33.38
15.52% Upside
High Forecast$50.00
Average Forecast$33.38
Low Forecast$19.00
TypeCurrent Forecast
2/8/23 to 2/8/24		1 Month Ago
1/9/23 to 1/9/24		3 Months Ago
11/10/22 to 11/10/23		1 Year Ago
2/8/22 to 2/8/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$33.38$30.25$30.25$12.75
Predicted Upside15.52% Upside92.34% Upside97.80% Upside166.64% Upside
Get Viking Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.


VKTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VKTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viking Therapeutics Stock vs. The Competition

TypeViking TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside15.52% Upside911.10% Upside8.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$35.00 ➝ $50.00+75.50%
12/4/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$32.00+122.38%
8/8/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$30.00+123.38%
5/30/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Dupuis
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
5/17/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$35.00 ➝ $37.00+50.13%
4/27/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$21.00 ➝ $33.00+68.80%
4/25/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$30.00 ➝ $35.00+64.09%
3/29/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$15.00 ➝ $19.00+18.53%
3/28/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$20.00 ➝ $31.00+105.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:39 PM ET.












VKTX Price Target - Frequently Asked Questions

What is Viking Therapeutics's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $33.38 with a high price target of $50.00 and a low price target of $19.00. Learn more on VKTX's analyst rating history.

Do Wall Street analysts like Viking Therapeutics more than its competitors?

Analysts like Viking Therapeutics more than other Medical companies. The consensus rating for Viking Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how VKTX compares to other companies.

Does Viking Therapeutics's stock price have much upside?

According to analysts, Viking Therapeutics's stock has a predicted upside of 90.39% based on their 12-month stock forecasts.

What analysts cover Viking Therapeutics?

Viking Therapeutics has been rated by Maxim Group, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:VKTX) was last updated on 2/8/2024 by MarketBeat.com Staff

My Account -